Literature DB >> 12516549

Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.

Vadim Y Taraban1, Tania F Rowley, Lyn O'Brien, H T Claude Chan, Linsey E Haswell, Michael H A Green, Alison L Tutt, Martin J Glennie, Aymen Al-Shamkhani.   

Abstract

This study addresses the relative importance of CD134 (OX40) and CD137 (4-1BB) in the costimulation of CD4+ and CD8+ T cells under comparable conditions of antigenic stimulation. We demonstrate that CD134 is capable of directly costimulating CD8+ T cells. However, costimulation of CD8+ T cells by CD134 is less potent than that triggered by CD137. The higher costimulatory activity of CD137, when compared with CD134, correlates well with its faster expression kinetics and higher levels on CD8+ T cells. Furthermore, induction of CD137 expression on CD8+ T cells is highly sensitive to low levels of TCR stimulation, which is in contrast with CD134. Conversely, CD134 is more effective than CD137 in costimulating CD4+ T cells. This, however, could not be attributed to differential expression. We also demonstrate that the transient nature of CD134 and CD137 expression on activated CD4+ T cells is the resultof proteolytic shedding. Consistent with the greater ability of CD137 to costimulate CD8+ T cells, stimulation of CD137 in vivo is considerably more effective than CD134 in augmenting anti-tumor immune responses. Therefore, agents that stimulate signaling via CD137 are likely to be more useful in clinical conditions where highly effective CD8+ CTL responses are required.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12516549     DOI: 10.1002/1521-4141(200212)32:12<3617::AID-IMMU3617>3.0.CO;2-M

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  56 in total

1.  CD137: costimulator turns suppressor?

Authors:  Aymen Al-Shamkhani
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

2.  Combining phage display with de novo protein sequencing for reverse engineering of monoclonal antibodies.

Authors:  Keith W Rickert; Luba Grinberg; Robert M Woods; Susan Wilson; Michael A Bowen; Manuel Baca
Journal:  MAbs       Date:  2016       Impact factor: 5.857

3.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

4.  Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model.

Authors:  Elizabeth W Newcomb; Yevgeniy Lukyanov; Noriko Kawashima; Michelle Alonso-Basanta; Shu-Chi Wang; Mengling Liu; Maria Jure-Kunkel; David Zagzag; Sandra Demaria; Silvia C Formenti
Journal:  Radiat Res       Date:  2010-04       Impact factor: 2.841

Review 5.  Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines.

Authors:  Lena Serghides; Mariana Vidric; Tania H Watts
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

6.  Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis.

Authors:  P Maerten; B S Kwon; C Shen; G De Hertogh; P Cadot; D M A Bullens; L Overbergh; C Mathieu; G Van Assche; K Geboes; P Rutgeerts; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

7.  A STAT3-dependent transcriptional circuitry inhibits cytotoxic gene expression in T cells.

Authors:  Thomas Ciucci; Melanie S Vacchio; Rémy Bosselut
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-27       Impact factor: 11.205

8.  Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Authors:  William L Redmond; Stefanie N Linch; Melissa J Kasiewicz
Journal:  Cancer Immunol Res       Date:  2013-11-11       Impact factor: 11.151

9.  Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.

Authors:  Susumu Fujiwara; Hiroshi Nagai; Noriko Shimoura; Shuntaro Oniki; Takayuki Yoshimoto; Chikako Nishigori
Journal:  J Invest Dermatol       Date:  2014-01-27       Impact factor: 8.551

10.  Decreased 4-1BB expression on HIV-specific CD4+ T cells is associated with sustained viral replication and reduced IL-2 production.

Authors:  Afework Kassu; Michelle D'Souza; Brian P O'Connor; Elizabeth Kelly-McKnight; Ramesh Akkina; Andrew P Fontenot; Brent E Palmer
Journal:  Clin Immunol       Date:  2009-04-29       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.